Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Breakthrough Injection Discovered for treatment of Geographic Atrophy
SYFOVRE™ (pegcetacoplan injection), a medication that treats geographic atrophy (GA) brought on by age-related macular degeneration, has received approval from the U.S. Food and Drug Administration. (AMD). It is the first and only treatment for GA to receive FDA clearance, and it did so on the basis of promising Phase III clinical trial findings from two studies...
Novel Drug Granted Breakthrough Therapy for Hypothalamic Obesity
The U.S. Food and Drug Administration (FDA) has designated setmelanotide, a brand-new medication developed by Rhythm Pharmaceuticals, as a breakthrough therapy for the management of hypothalamic obesity. The FDA's designation of a drug as a "breakthrough therapy" is meant to expedite the development and review...
Breakthrough Designation to Vaxcyte’s VAX-24 for IPD Prevention
The 24-valent pneumococcal conjugate vaccine, “VAX-24” from Vaxcyte has been given Breakthrough Therapy status by the US Food and Drug Administration (FDA) in order to prevent invasive pneumococcal illness in adults. The decision was based on topline findings from a Phase I/II proof-of-concept research that assessed the immunogenicity...
Imaging Agent for Onco-Nano Cancer Surgery Receives Breakthrough Therapy Device Designation
Pegsitacianine, an imaging agent that aids in the detection of malignancies in the peritoneal cavity after cytoreductive surgery, including ovarian cancer, has been given the Breakthrough Therapy designation by the FDA. When not in use, pegsitacianine is fluorescently dark, but when acidic tumours are present...
Novel Inhibitor approved as a Breakthrough Therapy for the Treatment of Acute Leukemia
The U.S. Food and Drug Administration has given the oral menin inhibitor Revumenib a breakthrough therapy designation (BTD). Revumenib is used to treat patients with relapsed or refractory acute leukemia harboring a KMT2A arrangement (KMT2Ar)....
New Medication Efanesoctocog Alfa Discovered For Hemophilia Treatment
Sanofi and Sobi have formed a partnership to collaborate on the development and commercialization of efanesoctocog alfa (BIVV001), a treatment for haemophilia A, a rare and life-threatening bleeding disorder....
Eli Lilly's New Drug Mounjaro™ to Treat Type 2 Diabetes
Mounjaro™ (tirzepatide) injection, developed by Eli Lilly and Company, is a novel, dual-targeted therapy that has been demonstrated to enhance glycemic control in adult patients with type 2 diabetes. In people with type 2 diabetes, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1...
Novel Mavacamten Discovered to Treat Obstructive Hypertrophic Cardiomyopathy (oHCM)
LianBio, discovered novel Mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin which is under investigation for the treatment of excessive cardiac contractility. It lowers the risk of cardiac muscle contractility by restricting...
First-of-its-Kind Digital Therapeutic BNT200 Discovered
Blue Note Therapeutics discovered first-of-its-kind prescription-only digital therapeutic BNT200 for the treatment of anxiety and depressive symptoms in adults patients with acute myeloid leukemia (AML) hospitalised for a regimen of high-intensity induction chemotherapy. BNT200 is a software as a medical device (SaMD) designed t0 treat anxiety and depressive...
Breakthrough CardiAMP Cell Therapy System Discovered for Heart Failure
BioCardia®, Inc revolutionizes heart failure treatment with the groundbreaking CardiAMP® Cell Therapy System. By harnessing the patient's own bone marrow cells and delivering them to the heart through a minimally invasive, catheter-based procedure, CardiAMP...
